SCHEMBL4033672

SCHEMBL4033672

COCC(NC(=O)c1ccc(Cl)s1)C(=O)Nc1ccc(N2CC3CCC2CC3)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 18/20 0.63
SMN1; SMN2 Q16637 1/20 0.37
PPM1D O15297 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030621 1.00 F10 (0.63) F10SMN1; SMN2PPM1D
SCHEMBL4033308 0.88 F10 (0.55) F10
SCHEMBL4479717 0.88 F10 (0.55) F10
SCHEMBL4033502 0.78 F10 (0.64) F10
SCHEMBL4033506 0.78 F10 (0.64) F10
SCHEMBL1379964 0.77 CYP2D6 (0.47) SMN1; SMN2
SCHEMBL4032350 0.77 F10 (1.00) F10
SCHEMBL4029046 0.77 F10 (1.00) F10
SCHEMBL6461995 0.75 F10 (0.67) F10SMN1; SMN2
SCHEMBL2568218 0.74 F10 (0.60) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562939-B1 CARBOXAMIDES MERCK PATENT GMBH (DE) 2009-01-21 EP claimed
US-20060052376-A1 Carboxamides MERCK PATENT GMBH (DE) 2006-03-09 US claimed
US-7579346-B2 (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors MERCK PATENT GMBH (DE) 2009-08-25 US disclosed
US-20060052376-A1 Carboxamides MERCK PATENT GMBH (DE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052376-A1 Carboxamides F11, F12, F10 F10 3/4885SMN1; SMN2 2636/4885PPM1D 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.